Status:
ACTIVE_NOT_RECRUITING
The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Breast Cancer Stage II
Breast Cancer Stage III
Eligibility:
All Genders
21+ years
Brief Summary
The objective of the study is to serve as a correlative study for patients enrolled on the RadCOMP trial (NCT02603341), a randomized phase III study of stage II and III breast cancer patients treated ...
Eligibility Criteria
Inclusion
- Eligible for and scheduled to receive radiation therapy on Radiation Therapy Oncology Group (RTOG) Trial 3510 (Pragmatic Phase III Randomized Trial of Proton vs Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial). (NCT02603341)
- Ability to understand and the willingness to sign a study-specific written informed consent document
Exclusion
- There are no exclusion criteria.
Key Trial Info
Start Date :
October 26 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03270072
Start Date
October 26 2017
End Date
December 31 2026
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114